Physician Assistant Program year 2023 Reported 2021–2023 Source: CMS Open Payments, 2026 publication

Sydney Holland

Physician Assistant Clearwater, KS Physician Assistant

NPI 1871043935 CMS profile 11254214

101 E Ross St, Clearwater, KS 67026

Open in the dashboard

General payments

$2,053

172 records reported · program years 2021–2023

Research payments

$0

Paid to them · None reported · program years 2021–2023

Ownership & investment interest

$0

None reported

Through program year 2023, Sydney Holland of Clearwater, KS is reported in the CMS Open Payments database as having received $2,053 across 172 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 80th percentile of Physician Assistant profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

3 rows
Year Kind Relative to this record's peak year Amount Records
2023 General $977 82
2022 General $803 72
2021 General $273 18

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Sydney Holland
  • Physician Assistant median
  • Middle half of Physician Assistant
  • National median

In program year 2025, general payments to Sydney Holland were reported at $0. Among 68,903 Physician Assistant profiles paid that year, the median was $184 and the middle half received between $57 and $620.

Show as a table
Year Sydney Holland Physician Assistant median Middle half National median
2019 $0 $34 $17–$122 $163
2020 $0 $33 $16–$78 $114
2021 $273 $132 $37–$438 $132
2022 $803 $155 $48–$522 $149
2023 $977 $167 $52–$557 $160
2024 $0 $178 $55–$600 $164
2025 $0 $184 $57–$620 $169

Breakdown

Who paid General payments · program years 2021–2023
  1. Lilly USA, LLC $440 38 payments
  2. AbbVie, Inc. $381 50 payments
  3. Novo Nordisk Inc $228 20 payments
  4. Salix Pharmaceuticals, a division of Bausch Health US, LLC $130 8 payments
  5. AstraZeneca Pharmaceuticals LP $115 8 payments
  6. Idorsia Pharmaceuticals US Inc $110 7 payments
  7. Otsuka America Pharmaceutical, Inc. $76 5 payments
  8. Sanofi-Aventis U.S. LLC $70 4 payments
  9. Janssen Pharmaceuticals, Inc $51 3 payments
  10. Merck Sharp & Dohme Corporation $50 3 payments
  11. Other $402 26 payments

Every payment, record by record

What the payments were for General payments · program years 2021–2023
  1. Food and Beverage $2,053 172 payments
Products named General payments · program years 2021–2023
  1. MOUNJARO $234 21 payments
  2. JARDIANCE $185 15 payments
  3. RYBELSUS $166 13 payments
  4. LINZESS $157 14 payments
  5. Ozempic $149 12 payments
  6. XIFAXAN $130 8 payments
  7. TRULANCE $130 8 payments
  8. UBRELVY $126 24 payments
  9. QUVIVIQ $110 7 payments
  10. TRULICITY $87 8 payments
  11. Other $1,100 89 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Records

172 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Physician Assistant in Kansas

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2023

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record